User menu

Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy

Bibliographic reference Giles, F.J. ; Abruzzese, E. ; Rosti, G. ; Kim, D.-W. ; Bhatia, R. ; et. al. Nilotinib is active in chronic and accelerated phase chronic myeloid leukemia following failure of imatinib and dasatinib therapy. In: Leukemia, Vol. 24, no.7, p. 1299-1301 (2010)
Permanent URL
  1. Giles F J, O'Dwyer M, Swords R, Class effects of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia, 10.1038/leu.2009.111
  2. O'Hare T., Eide C. A., Deininger M. W. N., Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia, 10.1182/blood-2007-03-066936
  3. Baccarani Michele, Cortes Jorge, Pane Fabrizio, Niederwieser Dietger, Saglio Giuseppe, Apperley Jane, Cervantes Francisco, Deininger Michael, Gratwohl Alois, Guilhot François, Hochhaus Andreas, Horowitz Mary, Hughes Timothy, Kantarjian Hagop, Larson Richard, Radich Jerald, Simonsson Bengt, Silver Richard T., Goldman John, Hehlmann Rudiger, Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet, 10.1200/jco.2009.25.0779
  4. Hochhaus A, O'Brien S G, Guilhot F, Druker B J, Branford S, Foroni L, Goldman J M, Müller M C, Radich J P, Rudoltz M, Mone M, Gathmann I, Hughes T P, Larson R A, Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia, 10.1038/leu.2009.38
  5. Quintas-Cardama A., Kantarjian H., Jones D., Nicaise C., O'Brien S., Giles F., Talpaz M., Cortes J., Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure, 10.1182/blood-2006-07-035493
  6. Goldman John M., Chronic Myeloid Leukemia: Reversing the Chronic Phase, 10.1200/jco.2009.26.5587
  7. Jabbour E, Hochhaus A, Cortes J, La Rosée P, Kantarjian H M, Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history, 10.1038/leu.2009.193
  8. Hiwase D. K., Saunders V., Hewett D., Frede A., Zrim S., Dang P., Eadie L., To L. B., Melo J., Kumar S., Hughes T. P., White D. L., Dasatinib Cellular Uptake and Efflux in Chronic Myeloid Leukemia Cells: Therapeutic Implications, 10.1158/1078-0432.ccr-07-5095
  9. Eadie L, Hughes T P, White D L, Nilotinib does not significantly reduce imatinib OCT-1 activity in either cell lines or primary CML cells, 10.1038/leu.2010.7
  10. Hiwase D K, White D, Zrim S, Saunders V, Melo J V, Hughes T P, Nilotinib-mediated inhibition of ABCB1 increases intracellular concentration of dasatinib in CML cells: implications for combination TKI therapy, 10.1038/leu.2009.242